Endo International plc Corporate Fact Sheet Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals. Endo’s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success. TM Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,400 people worldwide.* For more information about Endo International and our operating companies, please visit www.endo.com. *As of 10/31/2017 Our Operating Companies Our Vision for the Future Endo International plc Our organization will continue to Business Segments remain steadfast in our commitment U.S. Branded U.S. Generic International to deliver pharmaceutical products of Pharmaceuticals Pharmaceuticals Pharmaceuticals uncompromising quality and value with Operating Companies the highest levels of service. We will focus Endo Par Pharmaceutical Paladin Labs Pharmaceuticals Develops, manufactures and markets Providing innovative pharmaceutical on smart product selection, operational Develops and markets high-value, safe, innovative and cost-effective generic products for the Canadian market. quality branded pharmaceutical pharmaceutical products that help improve products to patients in need. patient quality of life. execution and continuous improvement, consistently improving how we work, and how we develop and deliver the products we make. We will work as a unified company, creating a cohesive and efficient structure that supports both our Generics and Branded businesses. We will build out Our Global Presence our portfolio and capabilities with a focus on core assets and businesses that are Chestnut Ridge, NY critical to our success. Par Pharmaceutical Headquarters Manufacturing and R&D Facilities Montebello, NY & Stratford, CT Montreal, Canada Distribution and Manufacturing Facilities Paladin Labs Headquarters At Endo, our high-performance organization Rye, NY Manufacturing Facilities has fostered an entrepreneurial culture Cranbury, NJ Manufacturing Facilities Rochester, MI Malvern, PA that emphasizes integrity and compliance. Manufacturing Facilities Endo U.S. Headquarters Horsham, PA Manufacturing Facilities Irvine, CA Performance-Driven, Integrity, Quality & Manufacturing Facilities Huntsville, AL Manufacturing Facilities Ireland Continuous Improvement, Customer Focus Endo International Global Headquarters and Collaboration are the Core Values that United Kingdom Par Laboratories Europe, Ltd. Sales, R&D drive and inspire our employees and enable us to deliver superior service and products, as well as make a positive impact on our patients and customers. Chennai, India Par R&D, Manufacturing and API Facilities www.endo.com Our Management Team Paul V. Campanelli* President, Chief Executive Officer and Director Joseph A. Barbarite Executive Vice President, Global Quality and Compliance Patrick Barry Senior Vice President, U.S. Branded Pharmaceuticals Blaise Coleman* Executive Vice President and Chief Financial Officer Terrance J. Coughlin* Executive Vice President and Chief Operating Officer Larry Cunningham Executive Vice President, Human Resources Jennifer E. Dubas Senior Vice President and Chief Compliance Officer Rahul Garella Senior Vice President, Head of International Pharmaceuticals Matthew Maletta* Executive Vice President, Chief Legal Officer Stephen Mock Senior Vice President, Investor Relations and Corporate Affairs Tony Pera* President, Par Pharmaceutical Brandon Rockwell Vice President, Business Development Dan Rudio* Senior Vice President, Controller and Chief Accounting Officer *Section 16(b) Executive Officers 2014 Our History Endo completes its divestiture of HealthTronics to Altaris Capital Partners, LLC Endo acquires Boca Pharmacal as part of Qualitest business Endo acquires Paladin Labs Endo and Paladin come together under 2010 Endo International plc. 2016 Endo acquires HealthTronics, Endo establishes new Endo winds down ASTORA Penwest Pharmaceuticals and global headquarters Women’s Health Business Qualitest Pharmaceuticals in Dublin, Ireland (formerly AMS Women’s Health) The U.S. FDA approves Endo acquires Endo makes a strategic decision FORTESTA® Gel for the treatment Grupo Farmacéutico SOMAR regarding their U.S. branded pain of low testosterone, or ‘Low T,’ Endo acquires DAVA business and returns BELBUCA™ also known as hypogonadism Pharmaceuticals as part to BioDelivery Sciences of Qualitest business International, Inc. (BDSI). 2012 Endo’s remaining pain products, Endo announces the The U.S. FDA approves including OPANA® ER, will be part aggregation of its operating AVEED® (testosterone of Endo’s portfolio of established 2006 companies as part of an undecanoate) injectable products and will no longer Endo receives FDA approval enterprise-wide branding testosterone replacement require promotional support for OPANA® and OPANA® ER, initiative and changes the therapy for men living with 2000 which represents the first parent company name to 1994 Endo Pharmaceuticals hypogonadism, or Low T internally developed NDAs Endo Health Solutions Inc. DuPont Merck establishes Holdings Inc. begins to trade to be granted FDA approval Endo as its generics entity publicly on NASDAQ (ENDP) 2017 Endo announces 2015 strategic change to Endo acquires Auxilium unify its operating 1920 2013 Pharmaceuticals, Inc. as part of Intravenous Products of model, enhance the 1997 Endo announces strategic Endo Pharmaceuticals business 2011 America, Inc. is founded as DuPont executives form change to focus on generics pipeline through 2009 Endo acquires American family run pharmaceutical Endo Pharmaceuticals Inc. in Endo acquires Indevus to providing quality products Endo completes acquisition of investment in hard- Medical Systems (AMS) company in New York City management buyout, obtaining diversify pharmaceutical through its operating Litha Healthcare Group to-produce assets & a broad portfolio of generic portfolio into urology technologies, transform companies, and announces Endo completes its divestiture of AMS and branded products the branded business into restructuring to improve Men’s and Prostate Health Businesses a highly focused Specialty operating margin and to Boston Scientific operational effectiveness business and divest Endo completes acquisition of specialty non-core assets generics and sterile injectables company Par Pharmaceutical Holdings Inc. Endo completes its Par is combined with Qualitest to divestiture of Litha create expanded U.S. Generics business Healthcare Group to Acino named Par Pharmaceutical Endo completes its Endo announces that the U.S. FDA divestiture of Grupo approves BELBUCA™ (buprenorphine) Farmacéutico SOMAR to buccal film for use in patients with Advent International chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate Our Corporate Information Endo Global Headquarters Investors/Media and Government Affairs Investors First Floor, Minerva House Stephen Mock Nina Goworek Simmonscourt Road Senior Vice President, Investor Relations Senior Director, Investor Relations Ballsbridge and Corporate Affairs 484-216-6657 Dublin 4 845-364-4833 [email protected] Ireland [email protected] +353 1 268 2000 Media Endo U.S. Headquarters Heather Zoumas-Lubeski 1400 Atwater Drive Senior Director, Corporate Affairs Malvern, PA 19355 484-216-6829 484-216-0000 [email protected] (800) 462-ENDO (3636) NASDAQ Ticker Symbol: ENDP Revised: November 2017 © 2017 Endo Pharmaceuticals Inc. www.endo.com.